Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine

Vaccine

Volumn 17, Issue 15-16, 1999, Pages 1919-1925

  Dagan, Ron ^a   Greenberg, David ^a   Goldenbertg Gehtman, Polina ^a   Vidor, Emmanuel ^b   Briantais, Philippe ^c   Pinsk, Vered ^a   Athias, Orna ^a   Dumas, Rafaele ^d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Pasteur Merieux Connaught USA   (United States)

^c Pasteur Merieux Connaught   (France)

^d Pasteur Merieux Connaught   (France)

Author keywords

Children; Hepatitis A vaccine; Immunogenicity; Safety

Indexed keywords

HEPATITIS A VACCINE;

ACTIVE IMMUNIZATION; ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEPATITIS A; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SKIN MANIFESTATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HEPATOVIRUS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; RADIOIMMUNOASSAY; SINGLE-BLIND METHOD; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0033537989     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00461-7     Document Type: Article

References (42)

1. Forbes A., Williams R. Increasing age: an important adverse prognostic factor in hepatitis A infection. J. R. Coll. Phys. (London). 22:1988;237-239.
2. Lieberman J.M., Greenberg D.P. Hepatitis A and B vaccines in children. Adv. Pediatr. Infect. Dis. 11:1996;333-363.
3. Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In: Hollinger F.B., Lemon S.M., Margolis H.S., editors. Viral hepatitis and liver disease. Baltimore: Williams and Wilkins, 1991. p. 76-78.
4. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatatanakool W., Kozik C., Suntayakorn S., Suknuntapong T., Safary A., Tang D., Boslego J. Protection against hepatitis A by an inactivated vaccine. J. Am. Med. Assoc. 271:1994;1328-1334.
5. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., Miller W., Shouval D., Wiens B., Calandra G., Ryan J., Provost P., Nalin D. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. New Engl. J. Med. 327:1992;453-457.
6. Richtmann R., Chaves R.L., Mendonca J.S., Konichi S.R., Mitre H.P., Takei K., Dietz K., Flehmig B. Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children. J. Med. Virol. 48:1996;147-150.
7. Mayorga O., Egger M., Zellmeyer M., Glück R., Herzog C., Frösner G.G. Efficacy of a virosome-formulated hepatitis A vaccine in an endemic region in Nicaragua: a randomized placebo-controlled trial [Abstract H4]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28 to October 1, 1997. Washington, DC: American Society for Microbiology, 1997. p. 298.
8. Prikazsky V., Olear V., Cernoch A., Safary A., Andre F.E. Interruption of an outbreak of hepatitis A in two villages by vaccination. J. Med. Virol. 44:1994;457-459.
9. McMahon B.J., Beller M., Williams J., Schloss M., Tanttila H., Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch. Pediatr. Adolesc. Med. 150:1996;733-739.
10. Averhoff F., Shapiro C.N., Hyams K.C., Burd L., Ward C., Ellena G. Use of inactivated hepatitis A vaccine to interrupt a communitywide hepatitis A outbreak [Abstract H73]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LO, September 15 to September 18, 1996. Washington, DC: American Society for Microbiology, 1996. p. 176.
11. Nalin D.R., Kuter B.J., Brown L., Patterson C., Calandra G., Werzberger A., Shouval D., Ellerbeck E., Block S., Bishop R., Wiens B., Schwartz S., Lewis J., Sitrin R., Provost P., Miller W., Ryan J. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J. Hepatol. 18:1993;S51-S55.
12. Clemens R., Safary A., Hepburn A., Roche C., Stanbury W.J., Andre F.E. Clinical experience with an inactivated hepatitis A vaccine. J. Infect. Dis. 171 (Suppl 1):1995;S44-S49.
13. Poovorawan Y., Theamboonlers A., Safary A. Single-dose hepatitis A vaccination: comparison of different dose levels in adolescents. Vaccine. 14:1996;1092-1094.
14. Lee S.D., Chan C.Y., Yu M.I., Wang Y.J., Lo K.J., Safary A. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters. Am. J. Gastroenterol. 91:1996;1360-1362.
15. Lee S.D., Lo K.J., Chan C.Y., Yu M.Y., Wang Y.J., Safary A. Immunogenicity of inactivated hepatitis A vaccine in children. Gastroenterol. 104:1993;1129-1132.
16. Horng Y.C., Chang M.H., Lee C.Y., Safary A., André F.E., Chen D.S. Safety and immunogenicity of hepatitis A vaccine in healthy children. Ped. Infect. Dis. J. 12:1993;359-362.
17. Dosseh B., Parent D., Lehner V., Aufrere A., Boudjadja A. Etude de la tolérance et de l'immunogénicité du vaccin inactivé anti-hépatite A chez trente enfants sains agés de 2 à 4 ans. Med. Mal. Infect. 23:1993;385-387.
18. Block S.L., Hedrick J.A., Tyler R.D., Smith A., Calandra G., Patterson C., Lewis J., Sitrin R., Miller W., Schwartz S., Wiens B., Nalin D. Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA™ registered trade mark) in rural Kentucky children. Ped. Infect. Dis. J. 12:1993;976-980.
19. Balcarek K.B., Bagley M.R., Pass R.F., Schiff E.R., Krause D.S. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J. Infect. Dis. 171 Suppl 1:1995;S70-S72.
20. McMahon B.J., Williams J., Bulkow L., Snowball M., Wainwright R., Kennedy M., Krause D. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and nonnative adults. J. Infect. Dis. 171:1995;676-679.
21. Aristegui J., Dal-Re R., Gonzalez A., Gallego M.S., Garrote E. Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2-5 years old. Infect. 23:1995;334-337.
22. Newcomer W., Rivin B., Reid R., Moulton L., Wolff M., Croll J., Johnson O., Brown L., Nalin D., Santosham M. Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children. Pediatr. Infect. Dis. J. 13:1994;640-642.
23. Findor J.A., Velasco M.C.C., Mutti J., Safary A. Response to hepatitis A vaccine in children after a single dose with a booster administration six months later. J. Trav. Med. 3:1996;156-159.
24. Troisi C.L., Hollinger F.B., Krause D.S., Pickering L.K. Immunization of seronegative infants with hepatitis A vaccine (Havrix; SB): a comparative study of two dosing schedules. Vaccine. 15:1997;1613-1617.
25. Shapiro C.N., Letson G.W., Kuehn D., Welty T., Krause D., Lambert S. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants [Abstract H61]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Fransisco, CA, September 17 to September 20, 1995. Washington, DC: American Society for Microbiology, 1995. p. 190.
26. Linder N., Karetnyi Y.V., Gidony Y., Ohel G., Levin E., Kuint J., Davidovitch N., Gidony I., Mendelson E., Barzilai A. Placental transfer of hepatitis A antibodies in full term and preterm infants. Pediatr. Infect. Dis. J. 16:1997;245-247.
27. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mort. Wkly. Rep. 1996, 45 (No. RR-15).
28. American Academy of Pediatrics Committee on Infectious Diseases (AAP) Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. Pediatrics. 98:1996;1207-1215.
29. CDC Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians and the American Medical Association. Morb. Mort. Wkly. Rep. 45:1996;1-16.
30. Anonymous Public health control of hepatitis A: memorandum from a WHO meeting. Bull. World Health Org. 73:1995;15-20.
31. Barnett E.D., Chen R. Children and international travel: immunizations. Pediatr. Infect. Dis. J. 14:1995;982-992.
32. Rosenblum L.S., Villarino M.E., Nainan O.V., Melish M.E., Hadler S.C., Pinsky P.P.et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J. Infect. Dis. 164:1991;476-482.
33. Thacker S.B., Addiss D.G., Goodman R.A., Holloway B.R., Spencer H.C. Infectious diseases and injuries in child day care: opportunities for healthier children. J. Amer. Med. Assoc. 268:1992;1720-1726.
34. Desenclos J.C.A., Maclafferty L. Community wide outbreak of hepatitis A linked to children in day care centres and with increased transmission in young adult men in Florida 1988-1989. J. Epidemiol. Comm. Health London. 47:1993;269-273.
35. Smith P.F., Grabau J.C., Werzberger A., Gunn R.A., Rolka H.R., Kondracki S.F., Gallo R., Morse D. The role of young children in a community-wide outbreak of hepatitis A. Epidemiol. Infect. 118:1997;243-252.
36. Sinlaparatsamee S., Niniem J., Kankao J., Theamboonlers A., Chumdermpadetsuk S., Poovorawan Y. An outbreak of hepatitis A in school children at Nakhon Si Thammarat, southern Thailand. S. As. J. Trop. Med. Public Health. 26:1995;104-108.
37. CDC Hepatitis A vaccination programs in communities with high rates of hepatitis A. Morb. Mort. Wkly. Rep. 46:1997;600-603.
38. Vidor E., Fritzell B., Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infect. 24:1996;447-458.
39. Frosner G.G., Overby L.R., Flehmig B. Serological investigation of patients and family contacts in an epidemic of hepatitis A. J. Med. Virol. 1:1977;163-173.
40. Miller W.J., Clark W., Hurni W.M., Kuter B., Schofield T., Nalin D.R. Sensitive assays for hepatitis A antibodies. J. Med. Virol. 41:1993;201-204.
41. Goubau P., Vangerven V., Safary A., Delem A.D., Knops J., d'Hondt E., Andre F., Desmyter J. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine. 10:1992;S114-S118.
42. Reuman P., Kubilis P., Hurni W., Brown L., Nalin D. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine. 15:1997;1157-1161.